Gangopadhyay A N, Sharma S P, Gopal S C, Gupta D K, Panjawani K, Sinha J K
Division of Pediatric Surgery and Plastic Surgery, Banaras Hindu University, Varanasi.
Indian Pediatr. 1996 Jan;33(1):31-3.
To evaluate the efficacy of intralesional triamcinolone in enhancing regression in various type of hemangiomas.
Outpatients department of a teaching hospital Subjects: One hundred and five patients with rapidly growing surface hemangioma. The age ranged from 1 month to 15 months (mean 7 months).
Intralesional triamcinolone administered at monthly intervals, ranging from single injection to 7 injections (mean 3.6 injections).
Regression of the hemangioma.
The overall response rate was 88.6% (excellent 51.4%, and good 37.2%). Maximum response was observed in children below 1 year of age (> 90%), lesions over the face (92.8%) and strawberry hemangiomas (99.9%).
Intralesional administration of triamcinolone devoid of systemic side effects and an effective initial modality for rapidly growing hermangiomas.
评估病灶内注射曲安奈德对促进各类血管瘤消退的疗效。
一家教学医院的门诊部。研究对象：105例快速生长的体表血管瘤患者。年龄范围为1个月至15个月（平均7个月）。
每月进行病灶内注射曲安奈德，注射次数从单次至7次不等（平均3.6次）。
血管瘤的消退情况。
总体有效率为88.6%（优51.4%，良37.2%）。1岁以下儿童（>90%）、面部病灶（92.8%）和草莓状血管瘤（99.9%）观察到最大反应。
病灶内注射曲安奈德无全身副作用，是快速生长的血管瘤有效的初始治疗方式。
